Chemplast Sanmar Limited — Q4 FY26 earnings call

Call held 26 May 2026

Management summary

Chemplast Sanmar faced a challenging FY26 marked by significant impairment and exceptional charges in its commodity PVC business due to market volatility and regulatory uncertainties. However, the Specialty Chemicals segment demonstrated strong growth, and the company commenced commercial production of R32 refrigerant gas. A committee has been formed to review strategic priorities and M&A opportunities to enhance long-term value.

Highlights

  • Q4 FY26 consolidated revenue grew 9% YoY to INR 1,256 crores.

  • Specialty Chemicals segment revenue increased 13% YoY to INR 475 crores, with volumes up 17% YoY.

  • Commercial production of R32 refrigerant gas commenced at the 2 kt swing plant.

  • Final findings from DGTR received for anti-dumping duty investigation against EU and Japan for Paste PVC.

  • Custom Manufactured Chemicals business shows early signs of recovery with a strong order book for FY27.

Concerns

  • FY26 was a challenging year with consolidated revenue of INR 4,224 crores and EBITDA of INR 198 crores.

  • Impairment loss of INR 898 crores recorded for the investment in CCVL due to structural reset in earnings outlook.

  • Exceptional charge of INR 150 crores for onerous contracts and raw material write-down in CCVL.

  • Persistent price pressures, excess global capacities, geopolitical disruptions, and PVC dumping impacted commodity business.

  • Regulatory support for PVC weakened, with QCOs rescinded and customs duty reduced (though temporary).

Key financials

4 periods

Headline

  • Net Debt (as of March 31, 2026)
    ₹1,419 Cr

Q4 FY26

  • Consolidated Revenue
    ₹1,256 Cr
    YoY +9%
  • Consolidated EBITDA
    ₹194 Cr
  • Consolidated Net Loss
    ₹45 Cr

FY26

  • Consolidated Revenue
    ₹4,224 Cr
  • Consolidated EBITDA
    ₹198 Cr
  • Consolidated Net Loss
    ₹280 Cr
  • Impairment Provision
    ₹898 Cr

CCVL FY26

  • Exceptional Item
    ₹150 Cr

What they filed

Q1 FY27: revenue up 2.3%, net profit down 175.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue993 1,058 1,151 1,100 1,033 +4%835 −21%1,256 +9%1,125 +2%
EBITDA26 32 37 17 43 +65%-57 −278%194 +424%-115 −776%
Net profit-31 -49 -54 -64 -51 −65%-119 −143%-45 +17%-176 −175%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

Share of Revenue (Q4 FY26)
₹1,256 Cr Total
  • Suspension PVC (CCVL) ₹661 Cr 52.6%
  • Specialty Chemicals ₹475 Cr 37.8%
  • Value-added Chemicals ₹120 Cr 9.6%

Capital allocation

high confidence
  • Capex Capex disclosed
    • MPB 3 Phase III expansion
    • R32 plants commissioning
    On the expansion side, progress on MPB 3 Phase III continued as planned during the quarter. The pipeline continues to gain momentum with 45-plus molecules progressing across various stages of development.
  • Debt Net ₹1,419 Cr
    As of 31st March 2026, the company's consolidated net debt stood at INR1,419 crores.
  • M&A Strategic Priorities & M&A Opportunities Other · Announced

    examine the strategic priorities for the company with a view to enhance the long-term value creation for stakeholders. The company may evaluate potential reorganization and M&A opportunities

    At this juncture, I would -- I wish to communicate that the Board has constituted a committee of three independent directors to examine the strategic priorities for the company with a view to enhance the long-term value creation for stakeholders. The company may evaluate potential reorganization and M&A opportunities and will table their findings to the Board for review and appropriate decision-making.
  • Liquidity Liquidity disclosed Impairment loss does not affect liquidity or the company's ability to operate the business.
    This is a non-cash adjustment that aligns the book value of the investment with the current economic realities. It does not affect liquidity or the company's ability to operate the business.

Guidance & targets

Specialty Chemicals

  • Paste PVC ADD implementation Specialty Chemicals · H1 FY27 · Medium confidence during first half of FY2026, '27
    while implementation of the ADD is now expected during first half of FY2026, '27.

    — S. Ganeshkumar

Custom Manufactured Chemicals

  • Revenue target Custom Manufactured Chemicals · next financial year · Medium confidence INR 1,000 crores
    So we are still comfortable with what I stated earlier that we anticipate getting to that level next financial year.

    — Krishna Rangachari

R32 Refrigerant Gas

  • Capacity R32 Refrigerant Gas · by end of the year · High confidence 14 kt
    And by the end of the year, as committed earlier, 14 kt capacity, but we are also providing design opportunities to debottleneck it further as required as the opportunity may arise.

    — S. Ganeshkumar

Suspension PVC

  • 7.5% import duty Suspension PVC · end of June · Medium confidence come back into the system
    Second is end of June, we hope that the 7.5% duty comes back into the system.

    — S. Ganeshkumar

  • Regulatory support Suspension PVC · Medium to long-term · Medium confidence very critical from the medium to long-term point of view
    regulatory support on the suspension PVC side is very critical from the medium to long-term point of view.

    — N. Muralidharan

What to watch in Q1 FY27

Paste PVC ADD implementation

H1 FY27
Current Final findings received, awaiting notification
Target Implementation of ADD

Why it matters

Crucial for improving realizations and margins in the Paste PVC business against imports.

We await the notification by the Finance Minister. This has already resulted in relatively lower import bookings from Europe, while implementation of the ADD is now expected during first half of FY2026, '27.

Risks & concerns

  • Challenging FY26 & Commodity Market Volatility

    high

    Persistent price pressures, excess global capacities, geopolitical disruptions, volatile feedstock/energy costs, and continued dumping of suspension PVC and paste PVC into India.

    Management acknowledged

  • Regulatory Uncertainty for PVC

    high

    Delay in ADD implementation, rescinding of QCOs, and temporary reduction in customs duty for PVC imports, weakening regulatory support.

    Management acknowledged

  • Impairment Loss on CCVL Investment

    high

    Non-cash impairment loss of INR 898 crores on CCVL investment due to a structural reset in the earnings outlook for the commodity business.

    Management acknowledged

  • Exceptional Charge for Onerous Contracts

    high

    INR 150 crores charge for onerous contracts and raw material write-down in CCVL, though expected to be reversed in the current financial year.

    Management acknowledged

  • Agrochemical Market Slowdown

    medium

    Slowdown in global agrochemical market impacting Custom Manufactured Chemicals business, though believed to be temporary.

    Management acknowledged

  • R32 Quota Allotment

    medium

    Uncertainty regarding government quota allotment for R32, which is critical for the large plant capacity. Management is confident based on overall country allocation.

    Analyst acknowledged, but confident

Q&A highlights

4 direct
Suspension PVC spread and FY27 outlook Partial
On a very, what you say, pessimistic end of the assumptions, yes, it is possible. But however, from what we also hear is the Chinese producers are also going through the stress. Second is end of June, we hope that the 7.5% duty comes back into the system. So that would add another what you say, $60, $70 to the pricing and the realization.

Analyst challenges management on the sustainability of the commodity business profitability given ongoing Chinese dumping and asks for FY27 outlook. Management acknowledges the pessimistic scenario but points to potential regulatory relief.

Asked by Sanjesh Jain

R32 capacity and Specialty Chemicals growth (45 molecules) Direct
So I will first take the R32 and then give it to Dr. Krishna to respond to the specialty chemicals. We have as in earlier calls, the quantities have been specified. So we are now on the verge of getting into the expansion. We are already progressing very well. And by the end of the year, as committed earlier, 14 kt capacity...

Clarifies the R32 capacity timeline and provides an update on the 45 molecules in the Custom Manufactured Chemicals division, confirming the growth trajectory.

Asked by Sanjesh Jain

CDMO pricing pressure and pipeline Direct
So our model is innovators, right? And we have not been impacted by what's been going on in the generic space because many of our products do not fall in that category. Most of the products that we supply now as well as the projects that we are working on, many of them are linked to new molecules, new pipeline molecules that the customers are -- have been working on.

Management clarifies that their CDMO model focuses on innovators, insulating them from generic market pricing pressures, and reiterates the strong pipeline of new molecules.

Asked by Ankur Periwal

Impairment loss and SPVC business outlook Partial
Nikhil, this is Murali. As you would appreciate, impairment tax is always done based on at a point in time, what is your view. And at the current point in time, with the volatility around and the uncertainty around regulatory support, the best estimate has been used, and that has been used for the evaluation purposes.

Analyst questions if the large impairment loss implies a negative long-term outlook for SPVC. Management explains it's a point-in-time assessment based on current volatility and regulatory uncertainty, leaving room for future review if conditions improve.

Asked by Nikhil Gandhi

R32 quota allotment and risk Direct
No. We are reasonably confident that. The reason we are reasonably confident of the quota... Allocation. Like we had said earlier, I think the overall formula is we believe is for the country. And we believe the recent circular also sort of highlight notification also highlights that. And I think with the capacities in place, we are reasonably confident of the availability of quota.

Analyst raises a critical risk regarding the large R32 plant capacity without confirmed quota. Management expresses confidence based on overall country allocation and recent circulars.

Asked by Deepak Ajmera

Committee mandate and M&A Direct
So it's a clean state. They will look at the businesses and see how efficiently they can reorganize the businesses to create value for all stakeholders. And we've also given the mandate would also include looking at possible M&A opportunities.

Analyst seeks clarity on the mandate of the newly formed committee, specifically if it implies a structural rethink of the business model to avoid commodity cycles. Management confirms the broad objective of value creation and M&A exploration.

Asked by Chetan Thacker

PVC market demand and new capacities (Adani/Reliance) Partial
We are hearing what you are hearing from the market, okay? So it's better that Reliance and Adani respond to this question.

Analyst asks about the impact of new large capacities from competitors like Adani and Reliance on the PVC market. Management deflects, stating it's better for those companies to comment, indicating potential competitive pressure.

Asked by Darshita Shah

2 min read 5 chapters

Detailed narrative

Q4 & FY26 Performance Overview

Chemplast Sanmar reported a challenging FY26 with consolidated revenue of INR 4,224 crores and EBITDA of INR 198 crores. Q4 FY26 saw a 9% YoY revenue growth to INR 1,256 crores and EBITDA of INR 194 crores, but a net loss of INR 45 crores. The year was significantly impacted by persistent price pressures, excess global capacities, and geopolitical disruptions, leading to an overall net loss of INR 280 crores for FY26.

Specialty Chemicals Segment Drives Growth

The Specialty Chemicals segment was a bright spot, recording Q4 sales of INR 475 crores, a 13% YoY increase, with volumes growing 17% YoY. This segment contributed 38% to the total Q4 revenue. Paste PVC, a key product in this segment, saw stable demand from footwear and healthy traction from automotive and upholstery, with the Cuddalore facility operating at 100% capacity.

Challenges and Impairment in Commodity Business

The Suspension PVC business, housed in CCVL, faced significant headwinds, with low-priced carbide PVC from China flooding the Indian market. This led to a sharp disconnect between PVC and feedstock VCM prices. Consequently, the company recorded a non-cash impairment loss of INR 898 crores on its investment in CCVL and an exceptional charge of INR 150 crores for onerous contracts and raw material write-down for FY26.

Strategic Review and Regulatory Environment

In response to the challenging environment, the Board constituted a committee of three independent directors to examine strategic priorities, including potential reorganization and M&A opportunities, to enhance long-term value. Management also highlighted weakening regulatory support for the PVC industry, with QCOs rescinded and temporary customs duty reductions, though they anticipate ADD implementation for Paste PVC in H1 FY27 and hope for the 7.5% duty to return for Suspension PVC by end of June 2026.

R32 Refrigerant Gas Commercialization and Custom Manufacturing Outlook

The company commenced commercial production of R32 refrigerant gas at its 2 kt swing plant in Mettur, with plans to scale up to 14 kt capacity by the end of calendar year 2026, targeting both domestic and export markets. The Custom Manufactured Chemicals division, despite a slowdown in the global agrochemical market, shows early signs of recovery with a strong order book for FY27 and a pipeline of over 45 molecules, targeting INR 1,000 crores revenue for FY27.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Chemicals earnings calls